Report Description of the Polycystic Ovarian Syndrome (PCOS/PCOD) Treatment Market
Research Scope and Assumption
- The report provides the market value for the base year 2020 and a yearly forecast up to 2028 in terms of revenue (USD billion)
- The key industry dynamics, regulatory scenario, reimbursement scenario, major market trends, and drug markets are evaluated to understand their impacts on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis
- We have used the combination of top-down and bottom-up approach for market sizing, analyzing key regional markets, dynamics, and trends for various solutions, services, and end uses
- All market estimates and forecasts have been validated through primary interviews with the Key Industry Players (KIPs) and secondary analysis
- Inflation has not been accounted for in order to estimate and forecast the market
- Numbers may not add up due to rounding off
Reason to buy the report:
- Facilitate decision-making based on strong current and forecast data for Polycystic Ovarian Syndrome Treatment Market
- Develop strategies based on the latest regulatory framework
- Strategically analyze micro-markets with respect to individual growth trends, future prospects, and their contribution to the market
- Analyze competitive developments such as expansions, investments, mergers & acquisitions, new product developments, and research & developments in the Polycystic Ovarian Syndrome Treatment market
- Analyze the opportunities in the market for stakeholders and draw a competitive landscape for market leaders
- To strategically profile key players and comprehensively analyze their market shares and core competencies
- We have technically sound team which do a deep dive research and also provide strategy based consulting analysis
Japan Polycystic Ovarian Syndrome (PCOS/PCOD) Treatment Executive Summary
Polycystic ovary syndrome or PCOS is a hormonal disorder that is common among women of childbearing age. PCOS causes infrequent or prolonged menstrual cycle or excess male hormone levels. Presently, there is no cure for PCOS, however, various medications are used to regulate menstrual cycle and to manage symptoms of PCOS.
Market Size and Key Findings
The Japan Polycystic Ovarian Syndrome (PCOS / PCOD) Treatment Market size stood at around USD XX billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Market Dynamics
Market Growth Drivers Analysis
Increase in prevalence of PCOS, rise in awareness among patient population with increase in adoption of combination therapy drives the polycystic ovarian syndrome treatment market growth. In addition, easy accessibility to PCOS therapeutics, rise in demand for PCOS medications, and technological advancements for detection of PCOS influence the market growth.
Market Restraints
Lack of approved therapeutics, and unknown etiology and pathophysiology of PCOS is anticipated to hamper the market growth. Furthermore, untapped potential offered by developing economies present lucrative opportunities for the growth of the polycystic ovarian syndrome treatment market during the forecast period. However, lack of specific treatment for PCOS disorder is expected to restrain the growth of the market. The rise in prevalence of PCOS is expected to augment the demand for PCOS treatment medications.
Competitive Landscape
Key Players
The major market players are focusing on symptomatic treatments and several have their drugs in clinical trials, but not approved for marketing. There is a growing focus on surgeries, for which many medical devices are inclined towards. Some of the major players in the market are Bayer AG, Ferring BV, Merck KGaA, Novartis, Pfizer, and Takeda, Teva Pharmaceutical Industries Limited, among others.
Products in Pipeline
Currently, no drugs are approved by the FDA and EMA for PCOS. However, oral contraceptives, insulin sensitizing agents, and aromatase inhibitors are used as first line agents for the treatment of irregular menstruation, diabetes, and facial hair growth respectively.
Notable Recent Deals
Evotec SE and Bayer AG announced the expansion of their partnership in women’s health indications with a new five-year, multi-target collaboration with participation from Celmatix Inc. to develop multiple clinical candidates for the treatment of polycystic ovary syndrome (“PCOS”). Under the terms of the agreement, both companies will contribute drug targets and a comprehensive set of high-quality technology platforms to jointly develop innovative treatment options.
Healthcare Policies and Regulatory Landscape
Policy changes and Reimbursement scenario
In 2006 the Japanese Society of Obstetrics and Gynecology (JSOG) proposed new, revised diagnostic criteria that in the future could also be valued internationally. Based on the new diagnostic criteria, the JSOG has also proposed the revised treatment criteria in 2008. In PCOS obese patients desiring children, weight loss and exercise is recommended.
